Kadri Altundag (Kadri Altundağ)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 104

Top Venues

Breast cancer research and treatment

Breast cancer (Tokyo, Japan)

Journal of surgical oncology

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Kadri Altundag
Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Kadri Altundag
Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation? Breast cancer (Tokyo, Japan) (2024)
Kadri Altundag
Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Kadri Altundag
Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density. Breast cancer (Tokyo, Japan) (2024)
Kadri Altundag
The Association of Taxanes With Breast Cancer-Related Lymphedema. Journal of surgical oncology (2024)
Kadri Altundag
Women with breast cancer who have second primary malignancies: Further information is still needed. Journal of surgical oncology (2024)
Kadri Altundag
Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation? Breast cancer (Tokyo, Japan) (2024)
Kadri Altundag
Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density. Breast cancer (Tokyo, Japan) (2024)
Kadri Altundag
Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation? Breast cancer (Tokyo, Japan) (2024)
Kadri Altundag
Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients. Breast cancer (Tokyo, Japan) (2024)
Kadri Altundag
Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Kadri Altundag
Is there any association between declined creatinine clearence and higher endoxifen levels in older patients with non-metastatic breast cancer? Breast cancer research and treatment (2023)
Kadri Altundag
Are breast cancer subtypes different in breast cancer patients with and without hepatitis C virus infection? Breast cancer (Tokyo, Japan) (2023)
Kadri Altundag
Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome. Breast cancer research and treatment 198 (1) (2023)
Kadri Altundag
High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer. Breast cancer research and treatment (2023)
Kadri Altundag
High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Kadri Altundag
The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ. Breast cancer research and treatment (2023)
Kadri Altundag
The use of pentoxifylline might enhance the effect of chemotherapy or radiotherapy in reducing tumor growth. Medical oncology (Northwood, London, England) 40 (6) (2023)
Kadri Altundag
The use of pentoxifylline might enhance the effect of chemotherapy or radiotherapy in reducing tumor growth. Medical oncology (Northwood, London, England) 40 (6) (2023)
Kadri Altundag
Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome. Breast cancer research and treatment 198 (1) (2023)
Kadri Altundag
Metastatic pure invasive lobular breast cancer or metastatic mixed invasive ductal and lobular breast cancer: are they different entities? Breast cancer research and treatment (2023)
Kadri Altundag
Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast cancer (Tokyo, Japan) (2023)
Kadri Altundag
Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Kadri Altundag
Metastatic pure invasive lobular breast cancer or metastatic mixed invasive ductal and lobular breast cancer: are they different entities? Breast cancer research and treatment 198 (3) (2023)
Kadri Altundag
The use of pentoxifylline might enhance the effect of chemotherapy or radiotherapy in reducing tumor growth. Medical oncology (Northwood, London, England) 40 (6) (2023)
Kadri Altundag
The association of telomere length with exercise and diet might be time-dependent in breast cancer survivors. Breast cancer research and treatment (2023)
Kadri Altundag
Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen? Breast cancer (Tokyo, Japan) (2023)
Kadri Altundag
High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Kadri Altundag
Interleukin-6 and C-Reactive protein in metastatic breast cancer patients treated with eribulin. Breast cancer research and treatment (2023)
Kadri Altundag
Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome. Breast cancer research and treatment 198 (1) (2023)
Kadri Altundag
Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome. Breast cancer research and treatment 198 (1) (2023)
Kadri Altundag
Is mixed invasive ductal lobular carcinoma distinct from invasive lobular carcinoma? Breast cancer research and treatment (2023)
Kadri Altundag
High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Kadri Altundag
Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome. Breast cancer research and treatment 198 (1) (2023)
Kadri Altundag
Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Kadri Altundag
High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Kadri Altundag
Possible mechanism behind the association between disrupted sleep quality and breast cancer outcome. Breast cancer research and treatment (2023)
Kadri Altundag
Reclassfying Estrogen Receptor-Positive/Basal Subtype by Using Immunohistochemistry Itself According to Grade and Estrogen Receptor Positivity Might Be Possible. JCO precision oncology 6 (2022)
Gülnihan Eren, Kadri Altundag
The Clinicopathological Characteristics of Pure and Mixed Invasive Micropapillary Breast Carcinomas: A Single Center Experience. Balkan medical journal 39 (4) (2022)
Kadri Altundag
Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer. Cancer 128 (16) (2022)
Kadri Altundag
The higher incidence of cases with poor prognostic factors in breast cancer patients who developed both breast cancer-related lymphedema and cellulitis might explain higher mortality. Journal of surgical oncology 126 (8) (2022)
Kadri Altundag
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients. Breast cancer research and treatment 196 (2) (2022)
Kadri Altundag
Specific Histological Subgroups in Invasive Lobular Carcinoma Might Affect Management Strategy in Invasive Lobular Carcinoma of the Breast. Annals of surgical oncology 28 (Suppl 3) (2021)
Kadri Altundag
Is there any association between a delay in surgery and nodal positivity in the ER-negative Her2 negative breast cancer subgroups? Journal of surgical oncology 124 (1) (2021)
Kadri Altundag
Are predictive factors for locoregional recurrence in skin-sparing and nipple-sparing mastectomies time-dependent? Journal of surgical oncology (2021)
Atakan Demir, Nil Molinas Mandel, Semra Paydaş, Gökhan Demir, Ozlem Er, Nazım Serdar Turhal, Sevil Bavbek, Yeşim Eralp, Pınar Mualla Saip, Emine Nilüfer Güler, Adnan Aydıner, Başak Oyan Uluç, Saadettin Kılıçkap, Necdet Üskent, Nuri Karadurmus, Muhammet Ali Kaplan, Mustafa Teoman Yanmaz, Hacer Demir, Özkan Alan, Taner Korkmaz, Polat Olgun, Özlem Sönmez, Kadri Altundag, Seyda Gunduz, Meral Günaldı, Murat Sarı, Ismail Beypinar, Gül Başaran
Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial Balkan medical journal 37 (2) (2020)
Kadri Altundag
Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients. Breast cancer research and treatment 184 (3) (2020)
Kadri Altundag
Orbital metastases in breast cancer patients with invasive lobular carcinoma. Journal of surgical oncology 122 (3) (2020)
Kadri Altundag
Probable association between increased systemic recurrence and the use of scalp cooling in breast cancer patients receiving (neo)adjuvant chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 29 (3) (2020)
Kadri Altundag
Late relapse rates in patients with early-stage hormone receptor-positive and HER2+ breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy. Journal of surgical oncology 121 (6) (2020)
Kadri Altundag
HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features. Breast cancer research and treatment 176 (3) (2019)
Kadri Altundag
Neo-adjuvant treatment in invasive apocrine carcinoma of the breast. The breast journal 25 (3) (2019)
Kadri Altundag
Larger Tumor Size Detected by Sonography Might Not Always Reflect Increased Risk of Axillary Lymph Node Metastasis in Patients With Breast Cancer. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 38 (9) (2019)
Kadri Altundag
Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life? Breast cancer research and treatment 176 (2) (2019)
Kadri Altundag
Metaplastic breast cancer: Some concerns about hormone receptor status and treatment schedules. The breast journal 25 (5) (2019)
Kadri Altundag
Patients with invasive lobular and ductal carcinoma or pleomorphic lobular carcinoma might increase pathologic complete response rate and lower mastectomy rates compared to classical lobular type. Journal of surgical oncology 120 (3) (2019)
Kadri Altundag
ER(+)/HER2(+) and ER-/HER2(+) breast cancers might have different intracranial recurrence patterns after brain-directed radiation for brain metastases. Breast cancer research and treatment 177 (1) (2019)
Kadri Altundag
Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment? Breast cancer research and treatment 179 (3) (2019)
Kadri Altundag
Is there any association between use of granulocyte colony-stimulating factor and chemotherapy-induced oral mucositis? European journal of cancer care 27 (6) (2019)
Kadri Altundag
HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment. Breast cancer research and treatment 175 (1) (2019)
Kadri Altundag
A closer look at familial Mediterranean fever cases in a large breast cancer dataset. Rheumatology international 39 (8) (2019)
Kadri Altundag
Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection. Breast cancer research and treatment 173 (2) (2018)
Kadri Altundag
Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases. Breast cancer research and treatment 172 (2) (2018)
Kadri Altundag
Taxane use in breast cancer and risk of brain metastases. Medical oncology (Northwood, London, England) 35 (4) (2018)
Kadri Altundag
Extent of metastases other than brain metastases may affect outcome in a breast cancer patients underwent resection of a brain metastases. The breast journal 24 (6) (2018)
Kadri Altundag
Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities. Journal of surgical oncology 117 (7) (2018)
Kadri Altundag
Breast cancer subtypes and local recurrence rate after surgery for bone metastasis to the extremities. Journal of surgical oncology 117 (7) (2018)
Kadri Altundag
Younger breast cancer patients under the age of 35 might have a better disease-free survival if they received ovarian function suppression more than 3 years. Breast cancer (Tokyo, Japan) 26 (2) (2018)
Kadri Altundag
Better pathological tumor characteristics might occur in recurrent metastatic breast cancer patients after 10-year metastatic free interval. Breast cancer research and treatment 173 (2) (2018)
Kadri Altundag
Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis? Journal of neuro-oncology 138 (1) (2018)
Kadri Altundag
Different Clinical and Pathologic Determinants Might be Possible to Predict Invasive Breast Cancer in Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 38 (6) (2018)
Kadri Altundag
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 27 (6) (2018)
Kadri Altundag
A positive conversion in hormone receptor and HER2 status might have an impact on survival after liver resection for breast cancer metastases. Irish journal of medical science 187 (4) (2018)
Kadri Altundag
The relationship between tumour size and nodal status is more incompatible in triple-negative tumours. Breast cancer research and treatment 171 (2) (2018)
Kadri Altundag
Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients. Breast cancer research and treatment 173 (1) (2018)
Kadri Altundag
Significant Family History of Breast Cancer may Further Increase Risk of Pre-malignant and Malignant Lesions in Specimens from Breast Reduction Surgery. Pathology oncology research : POR 25 (4) (2018)
Kadri Altundag
Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival. Breast cancer research and treatment 170 (2) (2018)
Kadri Altundag
Pure or mixed-type classical invasive lobular carcinoma might show different imaging features. Breast cancer research and treatment 172 (2) (2018)
Kadri Altundag
Detailed information about chemotherapy in breast control arm might affect cognitive sequelae compared with endocrine therapy patients. Breast cancer research and treatment 169 (1) (2018)
Kadri Altundag
Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy? Journal of neuro-oncology 135 (3) (2017)
Kadri Altundag
Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer. Journal of neuro-oncology 132 (3) (2017)
Kadri Altundag
Questions about lower inner zone tumors in early-stage breast cancer. Breast cancer (Tokyo, Japan) 24 (6) (2017)
Kadri Altundag
Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer. Breast cancer (Tokyo, Japan) 24 (6) (2017)
Kadri Altundag
Biopsy from Recurrent Lesion May Change Further Treatment Plan in Metastatic Breast Cancer. Nuclear medicine and molecular imaging 51 (2) (2017)
Kadri Altundag
Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival? Breast cancer research and treatment 162 (2) (2017)
Kadri Altundag
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers. Chinese journal of cancer 36 (1) (2017)
Kadri Altundag
Prognostic effect of neutrophil-lymphocyte ratio during concurrrent chemo-radiotherapy period in glioblastoma patients who did not receive dexamethasone. Journal of neuro-oncology 136 (1) (2017)
Kadri Altundag
More predictive markers were identified for trastuzumab-induced cardiotoxicity. Medical oncology (Northwood, London, England) 35 (1) (2017)
Kadri Altundag
Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients? Breast cancer research and treatment 168 (1) (2017)
Kadri Altundag
Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue? Breast cancer research and treatment 167 (3) (2017)
Kadri Altundag
Imaging modalities for the detection of distant metastases in breast cancer patients diagnosed in the 1970s and 1990s: Does it make any sense? Cancer cytopathology 125 (12) (2017)
Kadri Altundag
HER2 status might be independent determinant associated with no residual disease at surgical resection in patients with DCIS. Journal of surgical oncology 116 (6) (2017)
Kadri Altundag
Immune evasion might affect survival in laryngeal cancer patients with blood group O. Chinese journal of cancer 36 (1) (2017)
Kadri Altundag
Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival. Breast cancer research and treatment 167 (3) (2017)
Kadri Altundag
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer. The breast journal 23 (3) (2017)
Kadri Altundag
Tumor types, breast tumor subtypes and extension of systemic disease may influence outcome in cancer patients with brain metastases. Journal of neuro-oncology 132 (3) (2017)
Kadri Altundag
The effects of laterality in stage IV breast cancer patients at initial diagnosis; much work is needed! Breast cancer research and treatment 161 (3) (2017)
Kadri Altundag
Questions about Ki67 staining in luminal breast cancer. Breast cancer research and treatment 167 (2) (2017)
Kadri Altundag
Does longer disease-free interval affect the complete remission in metastatic breast cancer? Breast cancer (Tokyo, Japan) 24 (3) (2017)
Kadri Altundag
Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer 124 (4) (2017)

Kadri Altundag.css-eqlu8i{font-size:small;padding-left:4px;} (Kadri Altundağ)

Publication Activity (10 Years)

Top Topics

Top Venues

Kadri Altundag (Kadri Altundağ)